bioAffinity Technologies Reports First Quarter 2025 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2025
0mins
Should l Buy BIAF?
Source: Newsfilter
Financial Performance: bioAffinity Technologies reported a 276% increase in sales of its CyPath® Lung product year-over-year, generating $1.9 million in revenue for the first quarter of 2025, while also announcing strategic cost reductions expected to save approximately $3.8 million annually.
Operational Enhancements: The company improved processing efficiency for CyPath® Lung, increasing data acquisition throughput by 50% and reducing costs by over 25%, alongside positive patient case studies demonstrating the test's effectiveness in early lung cancer detection.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIAF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIAF
About BIAF
bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Urban-Gro Merges with Flash Sports, Expands into Media Sector
- Merger Transition: Urban-Gro's merger with Flash Sports and Media signifies a successful shift from indoor agriculture to sports media, enhancing its growth potential in new markets, with a stock surge of 731% in March.
- Energy Market Gains: Turbo Energy benefited from rising energy prices due to tensions in the Middle East, reporting a $53 million backlog in industrial orders in March, showcasing its strong position in energy security, despite a 6% drop in premarket trading.
- Gas Asset Appreciation: AleAnna announced significant increases in proved reserves across key Po Valley fields amid global LNG supply shocks, enhancing the strategic importance of its Italian gas assets, with a stock increase of over 25% in March.
- Sales Growth and Outlook: bioAffinity's lung diagnostic product CyPath showed strong sales growth, with a projected 100% growth by 2026, indicating a successful transition to revenue-generating operations, leading to a 233% stock increase in March.
See More
BioAffinity's CyPath Lung Test Shows Promising Results and Sales Growth
- Successful Non-Invasive Test Case: BioAffinity's CyPath Lung test was successfully applied to a 71-year-old former smoker, revealing multiple lung nodules, with results indicating inflammation rather than cancer, showcasing the test's effectiveness and potential in real-world applications.
- Significant Sales Growth Expected: The company anticipates that sales of the CyPath Lung test will exceed $963,000 in 2026, representing more than a 100% increase from 2025, reflecting strong market demand for non-invasive cancer detection.
- Stock Price Surge: BioAffinity's stock soared approximately 85% on Monday, breaking above its 200-day moving average, with a cumulative increase of over 160% in the past week, indicating strong investor confidence in the company's future prospects.
- Financial Condition Changes: Despite total revenue declining to $6.2 million and net loss widening to $14.9 million in 2025, the company raised $16.9 million to focus on the development of the CyPath Lung test, demonstrating its commitment to strategic transformation.
See More
BIAF Shares Jump 85%, Exceed 200-DMA for the First Time in Almost a Year – Here's What's Fueling the Surge
CyPath Lung Test Overview: BioAffinity Technologies' CyPath Lung test utilizes AI to analyze sputum samples, identifying potential cancer signals without invasive procedures. The test has shown promising results in a case study involving a 71-year-old former smoker.
Sales Projections: The company anticipates that sales of the CyPath Lung test will more than double by 2026, following an 87% increase in revenue for the full year 2025, reaching $963,000.
Stock Performance: BioAffinity's stock surged by 98% after reporting significant revenue growth, breaking above its 200-day moving average for the first time since April 2025, with a year-to-date gain of over 300%.
Research and Development: The company is advancing research in COPD and asthma diagnostics, with patient studies planned for this year, while also raising $16.9 million to fund growth initiatives.
See More
bioAffinity Technologies Launches New Lung Cancer Test Case Study
- Non-invasive Testing Advantage: bioAffinity Technologies' CyPath Lung test successfully provided a 'Unlikely Malignancy' result for a 71-year-old high-risk patient, avoiding costly and risky lung biopsy procedures, thereby reducing healthcare costs.
- Clinical Effectiveness: The test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in nodules less than 20 millimeters, indicating its potential in early lung cancer screening and effectively supporting physician decision-making.
- Patient Psychological Support: By alleviating patient anxiety regarding invasive procedures, CyPath Lung not only boosted patient confidence but also provided physicians with a reliable basis for follow-up imaging, promoting better medical decisions.
- Stock Performance Volatility: Despite BIAF's stock closing down 9.91% at $1.91 on Monday, it rebounded in pre-market trading, rising 15.64% to $2.20, reflecting positive market response to the new test case.
See More
bioAffinity Technologies 2025 Financial Overview
- Financial Performance: bioAffinity Technologies reported a FY GAAP EPS of -$8.66 with revenues of $6.2 million, indicating challenges in revenue growth and reflecting pressure in market competition.
- Operating Expense Reduction: Operating expenses decreased by 9% to $16.7 million in 2025, primarily due to strategic actions aimed at streamlining and reducing lab operation costs, which alleviated some financial pressure.
- R&D Investment: Research and development expenses were $1.4 million in 2025, slightly lower than the prior year, demonstrating the company's commitment to ongoing investment in lab operations and preclinical development despite financial losses.
- Cash Flow Status: As of December 31, 2025, cash and cash equivalents were $6.5 million, a significant increase from $1.1 million at the end of 2024, primarily due to $16.9 million raised in multiple financings in 2025 to support ongoing operations.
See More
bioAffinity Technologies Stock Soars on Strong CyPath Lung Results
- CyPath Lung Revenue Surge: bioAffinity reported an 87% year-over-year increase in CyPath Lung revenue for 2025, with test volumes soaring by 99%, indicating a 67% rise in orders from physician offices and clinics, reflecting enhanced market awareness and positive clinical experiences.
- Widening Net Loss: Despite revenue growth, bioAffinity's net loss widened from $9 million to $14.9 million, primarily due to changes in the fair value of warrants, expanded sales activities, and increased clinical development spending, highlighting financial pressures during the company's strategic shift.
- Improved Cash Flow: The company's cash and cash equivalents improved to $6.5 million at year-end, up from $1.1 million last year, bolstered by approximately $16.9 million raised in 2025 financings, enhancing its financial foundation for future business expansion.
- Optimistic Future Outlook: bioAffinity expects CyPath Lung unit sales to increase by over 100% in 2026, indicating that its efforts in commercialization and clinical validation are likely to drive future revenue growth and further solidify its market position.
See More
Urban-Gro Merges with Flash Sports, Expands into Media Sector
- Merger Transition: Urban-Gro's merger with Flash Sports and Media signifies a successful shift from indoor agriculture to sports media, enhancing its growth potential in new markets, with a stock surge of 731% in March.
- Energy Market Gains: Turbo Energy benefited from rising energy prices due to tensions in the Middle East, reporting a $53 million backlog in industrial orders in March, showcasing its strong position in energy security, despite a 6% drop in premarket trading.
- Gas Asset Appreciation: AleAnna announced significant increases in proved reserves across key Po Valley fields amid global LNG supply shocks, enhancing the strategic importance of its Italian gas assets, with a stock increase of over 25% in March.
- Sales Growth and Outlook: bioAffinity's lung diagnostic product CyPath showed strong sales growth, with a projected 100% growth by 2026, indicating a successful transition to revenue-generating operations, leading to a 233% stock increase in March.
See More
BioAffinity's CyPath Lung Test Shows Promising Results and Sales Growth
- Successful Non-Invasive Test Case: BioAffinity's CyPath Lung test was successfully applied to a 71-year-old former smoker, revealing multiple lung nodules, with results indicating inflammation rather than cancer, showcasing the test's effectiveness and potential in real-world applications.
- Significant Sales Growth Expected: The company anticipates that sales of the CyPath Lung test will exceed $963,000 in 2026, representing more than a 100% increase from 2025, reflecting strong market demand for non-invasive cancer detection.
- Stock Price Surge: BioAffinity's stock soared approximately 85% on Monday, breaking above its 200-day moving average, with a cumulative increase of over 160% in the past week, indicating strong investor confidence in the company's future prospects.
- Financial Condition Changes: Despite total revenue declining to $6.2 million and net loss widening to $14.9 million in 2025, the company raised $16.9 million to focus on the development of the CyPath Lung test, demonstrating its commitment to strategic transformation.
See More
BIAF Shares Jump 85%, Exceed 200-DMA for the First Time in Almost a Year – Here's What's Fueling the Surge
CyPath Lung Test Overview: BioAffinity Technologies' CyPath Lung test utilizes AI to analyze sputum samples, identifying potential cancer signals without invasive procedures. The test has shown promising results in a case study involving a 71-year-old former smoker.
Sales Projections: The company anticipates that sales of the CyPath Lung test will more than double by 2026, following an 87% increase in revenue for the full year 2025, reaching $963,000.
Stock Performance: BioAffinity's stock surged by 98% after reporting significant revenue growth, breaking above its 200-day moving average for the first time since April 2025, with a year-to-date gain of over 300%.
Research and Development: The company is advancing research in COPD and asthma diagnostics, with patient studies planned for this year, while also raising $16.9 million to fund growth initiatives.
See More
bioAffinity Technologies Launches New Lung Cancer Test Case Study
- Non-invasive Testing Advantage: bioAffinity Technologies' CyPath Lung test successfully provided a 'Unlikely Malignancy' result for a 71-year-old high-risk patient, avoiding costly and risky lung biopsy procedures, thereby reducing healthcare costs.
- Clinical Effectiveness: The test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in nodules less than 20 millimeters, indicating its potential in early lung cancer screening and effectively supporting physician decision-making.
- Patient Psychological Support: By alleviating patient anxiety regarding invasive procedures, CyPath Lung not only boosted patient confidence but also provided physicians with a reliable basis for follow-up imaging, promoting better medical decisions.
- Stock Performance Volatility: Despite BIAF's stock closing down 9.91% at $1.91 on Monday, it rebounded in pre-market trading, rising 15.64% to $2.20, reflecting positive market response to the new test case.
See More
bioAffinity Technologies 2025 Financial Overview
- Financial Performance: bioAffinity Technologies reported a FY GAAP EPS of -$8.66 with revenues of $6.2 million, indicating challenges in revenue growth and reflecting pressure in market competition.
- Operating Expense Reduction: Operating expenses decreased by 9% to $16.7 million in 2025, primarily due to strategic actions aimed at streamlining and reducing lab operation costs, which alleviated some financial pressure.
- R&D Investment: Research and development expenses were $1.4 million in 2025, slightly lower than the prior year, demonstrating the company's commitment to ongoing investment in lab operations and preclinical development despite financial losses.
- Cash Flow Status: As of December 31, 2025, cash and cash equivalents were $6.5 million, a significant increase from $1.1 million at the end of 2024, primarily due to $16.9 million raised in multiple financings in 2025 to support ongoing operations.
See More
bioAffinity Technologies Stock Soars on Strong CyPath Lung Results
- CyPath Lung Revenue Surge: bioAffinity reported an 87% year-over-year increase in CyPath Lung revenue for 2025, with test volumes soaring by 99%, indicating a 67% rise in orders from physician offices and clinics, reflecting enhanced market awareness and positive clinical experiences.
- Widening Net Loss: Despite revenue growth, bioAffinity's net loss widened from $9 million to $14.9 million, primarily due to changes in the fair value of warrants, expanded sales activities, and increased clinical development spending, highlighting financial pressures during the company's strategic shift.
- Improved Cash Flow: The company's cash and cash equivalents improved to $6.5 million at year-end, up from $1.1 million last year, bolstered by approximately $16.9 million raised in 2025 financings, enhancing its financial foundation for future business expansion.
- Optimistic Future Outlook: bioAffinity expects CyPath Lung unit sales to increase by over 100% in 2026, indicating that its efforts in commercialization and clinical validation are likely to drive future revenue growth and further solidify its market position.
See More
